Advertisement
Research Article

A Longitudinal Trial Comparing Chloroquine as Monotherapy or in Combination with Artesunate, Azithromycin or Atovaquone-Proguanil to Treat Malaria

  • Miriam K. Laufer mail,

    mlaufer@medicine.umaryland.edu

    Affiliation: Malaria Group, Howard Hughes Medical Institute/Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, United States of America

    X
  • Phillip C. Thesing,

    Affiliation: Malaria Group, Howard Hughes Medical Institute/Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, United States of America

    X
  • Fraction K. Dzinjalamala,

    Affiliation: Blantyre Malaria Project, University of Malawi College of Medicine, Blantyre, Malawi

    X
  • Osward M. Nyirenda,

    Affiliation: Blantyre Malaria Project, University of Malawi College of Medicine, Blantyre, Malawi

    X
  • Rhoda Masonga,

    Affiliation: Blantyre Malaria Project, University of Malawi College of Medicine, Blantyre, Malawi

    X
  • Matthew B. Laurens,

    Affiliation: Malaria Group, Howard Hughes Medical Institute/Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, United States of America

    X
  • Abbie Stokes-Riner,

    Affiliation: EMMES Corporation, Rockville, Maryland, United States of America

    X
  • Terrie E. Taylor,

    Affiliation: College of Osteopathic Medicine, Michigan State University, East Lansing, Michigan, United States of America

    X
  • Christopher V. Plowe

    Affiliation: Malaria Group, Howard Hughes Medical Institute/Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, United States of America

    X
  • Published: August 17, 2012
  • DOI: 10.1371/journal.pone.0042284

Viewed info

Cited info

Saved info

Discussed info

Questions or concerns about usage data? Please let us know.